TY - JOUR
TI - Cardiovascular complications of metastatic colorectal cancer treatment
AU - Keramida, K.
AU - Charalampopoulos, G.
AU - Filippiadis, D.
AU - Tsougos, E.
AU - Farmakis, D.
JO - WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
PY - 2019
VL - 10
TODO - 4
SP - 797-806
PB - AME Publishing Company
SN - null
TODO - 10.21037/jgo.2019.03.04
TODO - aflibercept;  antineoplastic agent;  B Raf kinase;  bevacizumab;  capecitabine;  cetuximab;  cytotoxic agent;  fluorouracil;  panitumumab;  Ras protein;  regorafenib, acute heart infarction;  angina pectoris;  artery thrombosis;  atrial fibrillation;  brain disease;  bronchospasm;  cancer chemotherapy;  cardiogenic shock;  cardiotoxicity;  cardiovascular disease;  coronary artery spasm;  death;  deep vein thrombosis;  dehydration;  drug hypersensitivity;  dyspnea;  endothelial dysfunction;  fever;  heart arrhythmia;  heart failure;  heart infarction;  heart muscle ischemia;  heart palpitation;  heart right bundle branch block;  heart ventricle fibrillation;  high risk patient;  human;  hypertension;  hypertension encephalopathy;  hypokalemia;  hypomagnesemia;  hypotension;  hypoxia;  lung embolism;  metastatic colorectal cancer;  myocarditis;  pericarditis;  Review;  shock;  subarachnoid hemorrhage;  sudden cardiac death;  takotsubo cardiomyopathy;  thorax pain;  thrombophlebitis;  urticaria;  venous thromboembolism
TODO - Colorectal cancer (CRC) is the third most common malignancy in men and the second in women and the fourth cause of cancer death. Survival rates decrease greatly according to the stage of the disease at the time of diagnosis. Approximately 50% of CRC patients will develop metastatic disease (mCRC) with survival and prognosis depending on the timing of metastatic development, and the localization and number of metastatic sites. The overall survival of patients with mCRC has been significantly improved over the last years from approximately 12 to more than 30 months with the integration of multiple cytotoxic agents and targeted therapies. The optimal therapeutic strategy depends on the general condition and performance status of the patient, the resectability or not of metastases and the mutational status of the tumor in terms of BRAF and RAS. Cardiovascular (CV) complications of mCRC treatment may develop peri-operatively and mostly during chemotherapy. During first-line treatment, 90% of patients experience more than one adverse event (AE) and 39% of them are CV. Angina, hypertension, arrhythmias, arterial and venous thrombotic events (VTEs), heart failure (HF) and death are the main CV events resulting from the applied chemotherapy regimens. Cardio-oncology consultation for identification of high-risk patients, proper monitoring during and after therapy and timely intervention would allow the successful prevention and the efficient management of cardiotoxicity, rendering the patient able to receive the indicated cancer therapy and improving the overall outcome. © Journal of Gastrointestinal Oncology. All rights reserved.
ER -